Proven Relief for Hot Flushes
Vivelle-Dot® Significantly Reduces the Frequency of Moderate to Severe Hot Flushes
For your patients’ moderate to severe vasomotor symptoms associated with menopause, Vivelle-Dot 0.0375, 0.05, 0.075, and 0.1 mg/day offer effective relief. In a 12-week clinical study, Vivelle® (estradiol transdermal system) delivered significant reductions in the frequency of daily hot flushes across dosage strengths*1
Both doses were significantly superior to placebo at all time points (P<0.05). Differences between the 2 active doses were not significant. Results from a 12-week, multicenter, double-blind, randomized, placebo-controlled study in 122 healthy women with moderate to severe menopausal symptoms to evaluate the safety and efficacy of 2 doses of Vivelle. All women had been postmenopausal for at least 1 year or had been oophorectomized at least 2 months prior to enrollment. Subjects underwent 4 weeks of placebo run-in prior to randomization into 1 of the 3 treatment arms.